Long non-coding RNA LINC01234 regulates proliferation, migration and invasion via HIF-2α pathways in clear cell renal cell carcinoma cells

Feilong Yang¹, Cheng Liu¹, Guojiang Zhao¹, Liyuan Ge¹, Yimeng Song¹, Zhigang Chen¹, Zhuo Liu¹, Kai Hong Corresp.¹, Lulin Ma Corresp.¹

¹Department of Urology, Peking University Third Hospital, Beijing, China

Corresponding Authors: Kai Hong, Lulin Ma
Email address: kenhong99@hotmail.com, malulin@medmail.com.cn

Long non-coding RNAs (lncRNAs) have been proved to have an important role in different malignancies including clear cell renal cell carcinoma (ccRCC). However, their role in disease progression is still not clear. The objective of the study was to identify lncRNA-based prognostic biomarkers and further to investigate the role of one lncRNA LINC01234 in progression of ccRCC cells. We found that six adverse prognostic lncRNA biomarkers including LINC01234 were identified in ccRCC patients by bioinformatics analysis using The Cancer Genome Atlas (TCGA) database. LINC01234 knockdown impaired cell proliferation, migration and invasion in vitro as compared to negative control. Furthermore, the epithelial-mesenchymal transition (EMT) was inhibited after LINC01234 knockdown. Additionally, LINC01234 knockdown impaired hypoxia-inducible factor-2α (HIF-2α) pathways including a suppression of the expression of HIF-2α, vascular endothelial growth factor A (VEGFA), epidermal growth factor receptor (EGFR), c-Myc, Cyclin D1 and MET. Together, these datas showed that LINC01234 was likely to regulate the progression of ccRCC by HIF-2α pathways, and LINC01234 was both a promising prognostic biomarker and a potential therapeutic target for ccRCC.
Long Non-coding RNA LINC01234 Regulates Proliferation, Migration and Invasion via HIF-2α Pathways in Clear Cell Renal Cell Carcinoma Cells

Feilong Yang¹, Cheng Liu¹, GuoJiang Zhao¹, Liyuan Ge¹, Yimeng Song¹, Zhigang Chen¹, Zhuo Liu¹, Kai Hong¹, Lulin Ma¹

¹ Department of Urology, Peking University Third Hospital, Beijing, China

Corresponding Author:
Lulin Ma¹
49 North Garden Road, Haidian District, Beijing 100191, China
Email address: malulin@medmail.com.cn
Kai Hong¹
49 North Garden Road, Haidian District, Beijing 100191, China
Email address: kenhong99@hotmail.com

Abstract
Long non-coding RNAs (lncRNAs) have been proved to have an important role in different malignancies including clear cell renal cell carcinoma (ccRCC). However, their role in disease progression is still not clear. The objective of the study was to identify lncRNA-based prognostic biomarkers and further to investigate the role of one lncRNA LINC01234 in progression of ccRCC cells. We found that six adverse prognostic lncRNA biomarkers including LINC01234 were identified in ccRCC patients by bioinformatics analysis using The Cancer Genome Atlas (TCGA) database. LINC01234 knockdown impaired cell proliferation, migration and invasion in vitro as compared to negative control. Furthermore, the epithelial-mesenchymal transition (EMT) was inhibited after LINC01234 knockdown. Additionally, LINC01234 knockdown impaired hypoxia-inducible factor-2α (HIF-2α) pathways, including a suppression of the expression of HIF-2α, vascular endothelial growth factor A (VEGFA), epidermal growth factor receptor (EGFR), c-Myc, Cyclin D1 and MET. Together, these datas showed that LINC01234 was likely
to regulate the progression of ccRCC by HIF-2α pathways, and LINC01234 was both a promising prognostic biomarker and a potential therapeutic target for ccRCC.

Introduction

In 2018, it was predicted that 403,262 new cases would be diagnosed with kidney cancer in 185 countries and 175,098 cases would be dead (Bray et al. 2018). In 36 kinds of cancers, the morbidity and mortality of kidney cancer were 2.2% and 1.8% respectively (Bray et al. 2018). Clear cell RCC (ccRCC) is the most common subtype of RCC and it accounts for 75% (Song et al. 2018). Although surgery is still the preferred therapeutic option for the localized and locally advanced ccRCC, the long-term prognosis remains unsatisfactory and unpredictable. Current existed evaluation approach for prognosis of ccRCC is mainly based on clinicopathologic data, such as TNM staging. However, it does not reflect the biological heterogeneity of cancer (Cheng 2018). Therefore, there is an urgent need for discovering a new prognostic model and biomarkers for ccRCC. Moreover, it is necessary to understand the molecular mechanisms of the prognostic biomarkers underlying ccRCC development.

Long non-coding RNA (lncRNA) is a kind of RNA transcripts with a length of > 200 nucleotides. Unlike mRNA, it does not encode proteins. Currently, it is reported that lncRNA is engaged in numerous important biological processes and the development and progression of numerous human diseases, including ccRCC (Esteller 2011; Gupta et al. 2010; Jin et al. 2017; Martens-Uzunova et al. 2014; Ponting et al. 2009; Quinn & Chang 2016; Rinn & Chang 2012). The overexpression, deficiency or mutation of lncRNA are associated with the tumor formation, progression, metastasis and prognosis in many human malignancies including ccRCC (Esteller 2011; Ghaffar et al. 2018; Gupta et al. 2010; He et al. 2018; Jin et al. 2017; Martens-Uzunova et al. 2014). However, the functions of the majority of lncRNA are not well understood. In our study, we constructed a lncRNA-based prognostic model and identified six lncRNAs as independent prognostic biomarkers in ccRCC, including LINC01234.

Several studies showed that LINC01234 was upregulated and had oncogenic potentials in several cancers, such as gastric cancer (Chen et al. 2018), esophageal cancer (Ghaffar et al. 2018), and colorectal adenocarcinoma (He et al. 2018). Most ccRCC are associated with loss of von Hippel-Lindau tumor suppressor (pVHL) function and deregulation of hypoxia pathways (Schödel et al. 2016). Adaptation to hypoxia plays an important role in the progression of ccRCC (Garje et al. 2018). Hypoxia is mediated via hypoxia-inducible factors (HIFs) HIF-1α and HIF-2α (Semenza 2012). Recently, studies showed that HIF-2α, rather than HIF-1α, was a predominant driver in renal cancer progression (Keith et al. 2011). Although HIF-1α can act as a ccRCC tumor suppressor, HIF-1α activity is commonly diminished by chromosomal deletion in ccRCC (Schödel et al. 2016). Conversely, HIF-2α has emerged as the key HIF isoform acting as an
oncogene that is essential for ccRCC tumor progression (Meléndez-Rodríguez et al. 2018; Schödel et al. 2016). The polymorphisms at the HIF-2α gene locus predispose to the development of ccRCC, and HIF-2α promotes tumor growth (Schödel et al. 2016). Indeed, preclinical and clinical data have shown that pharmacological inhibitors of HIF-2α can efficiently inhibit ccRCC growth (Meléndez-Rodriguez et al. 2018). However, the role of LINC01234, as well as the relationship between LINC01234 and HIF-2α in ccRCC remains unclear. In the present study, we showed that LINC01234 was likely to regulate the progression of ccRCC by HIF-2α pathways. Therefore, LINC01234 might serve as a promising prognostic biomarker and a potential therapeutic target for patients with ccRCC.

**Materials & Methods**

**LncRNA expression and clinical datasets of ccRCC cases**

The TCGA Research Network was available at http://cancergenome.nih.gov/ (Deng et al. 2016). The datasets for ccRCC cases within the TCGA database were downloaded using the GDC Data Portal. The version of the dataset was: Data Release 14.0-December 18, 2018.

**Differentially expression analysis to identify differentially expressed lncRNAs**

Differentially expression analysis was performed as previously described (Yang et al. 2019). A volcano plot was plotted for the differentially expressed lncRNAs.

**Univariate cox regression and least absolute shrinkage and selection operator (LASSO) regression to identify key prognostic lncRNAs**

The univariate cox regression was performed for the differentially expressed lncRNAs. Then, the statistically significant lncRNAs (p < 0.05) were used for LASSO regression to identify key prognostic lncRNAs. The univariate cox regression and LASSO regression were performed as previously described (Yang et al. 2019).

**Multivariate cox regression to establish the prognostic model**

The multivariate cox regression was performed for the key prognostic lncRNAs as previously described (Yang et al. 2019). It calculated the risk score for each patient. Based on the median of the risk score, all patients were divided into the high-risk group and low-risk group. A heatmap was plotted to present the expression levels of the key prognostic lncRNAs in the two groups. And a forest plot was plotted to present the hazard ratio (HR) and 95% confidence interval (CI) for the key prognostic lncRNAs.

**ROC curve and C-index to evaluate the prognostic model**

The 3-year and 5-year time-dependent receiver operating characteristic (ROC) curves, the area under the ROC curves (AUCs) and the C-index were performed as previously described (Yang et al. 2019).

**Kaplan–Meier (K–M) survival analysis to identify independent prognostic biomarkers**
The R package ‘survival’ (cran.r-project.org/web/packages/survival/index.html) was used for K–M survival analysis. Firstly, the K–M survival analysis was performed for the high-risk group and the low-risk group. Then K–M survival curves were plotted individually for each statistically significant lncRNA from the result of the multivariate cox regression.

Validation of the expression and prognostic significance of the independent prognostic biomarkers

Gene Expression Profiling Interactive Analysis (GEPIA) server (Tang et al. 2017) is a newly developed interactive web server and has been running for three years. It was used for analyzing the RNA sequencing expression data computed by a standard processing pipeline. Therefore, we validated the expression levels and prognostic significance of the independent prognostic biomarkers in patients with ccRCC via GEPIA server according to their Ensembl ID.

Cell culture

Human RCC cells Caki-2 and A498 (Chinese Academy of Medical Sciences Shanghai Cell Bank) were cultured in RPMI 1640 medium (Gibco, USA) containing 10% fetal bovine serum (FBS) (Gibco, USA), 100 U/ml penicillin (Sigma-Aldrich, St Louis, MO) and 100 μg/ml streptomycin (Sigma-Aldrich). All cells were routinely cultured in 5% CO2 at 37°C.

Lentivirus-mediated shRNA transfection

The recombinant lentivirus with short hairpin RNA (shRNA) and the corresponding control lentivirus were purchased from Genechem (Shanghai, China). Transfection in vitro was performed following the manufacturer's protocols. Stable shRNA-expressing colonies were selected using puromycin (Solarbio, Beijing, China). The target sequences of shRNA were as follows: 5’- CCTCGGTCTCAGTTTCTCCATTTAT-3’ (shRNA) and 5’- TTCTCCGAACGTGTCACGT-3’ (control) respectively.

RNA extraction, reverse transcription and real-time quantitative PCR (qPCR)

RNA extraction and reverse transcription were performed as previously described (Wang et al. 2020). qPCR was performed using SYBR Green Realtime PCR Master Mix (TOYOBO, Osaka, Japan) in the QuantStudio 5 Real-Time PCR System (Thermo Fisher Scientific, USA). The PCR primers are shown in Supplementary Table S1. The relative expression levels of genes were calculated using the 2^-ΔΔCt method relative to GAPDH.

CCK-8 cell proliferation assay

Cells stably expressing LINC01234 shRNA or control vector were plated into 96-well plates (2000 cells per well) and incubated at 37°C under 5% CO2 for 1, 2, 3 or 4 days respectively. Then CCK-8 solution (Dojindo, Japan) was added into the culture medium, and the optical density (OD) at 450 nm was measured with a Microplate Reader (Bio-Rad Laboratories Inc, Hercules, CA, USA) after incubation for 1.5 h. Each group had five duplicates and the experiment was performed in triplicate.
**Cell colony formation assay**

Cells stably expressing LINC01234 shRNA or control vector were plated into 10 cm culture dish (1500 cells per dish) and incubated for 14 days. Wells were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The cell colonies with >50 cells were counted. Each group had three duplicates and the experiment was performed in triplicate.

**Transwell assays**

Transwell assays including migration assays and invasion assays were performed as previously described (Wang et al. 2020). Each group had three duplicates and the experiment was performed in triplicate.

**Western blots**

Western blots were performed as described (Liu et al. 2013; Yang et al. 2018). Total cellular protein was extracted using RIPA buffer (Beyotime, Shanghai, China) with 1% of 100 mM PMSF (Solarbio, Beijing, China). Protein concentration was quantified using a BCA Protein Quantitative Kit (Beyotime, Shanghai, China). Briefly, 30 μg of protein was resolved by 10% SDS–PAGE, and transferred to a PVDF membrane (Millipore, Billerica, MA). The membrane was blocked with 5% skim milk and then probed with rabbit or mouse anti-human primary antibodies respectively. Next, the membranes were incubated with corresponding HRP-conjugated goat anti-rabbit or anti-mouse IgG (1:1000 dilution) (CST, Boston, USA) and detected with Western Blotting Luminol Reagent (Santa Cruz, CA, USA). The experiment was performed in triplicate. Epithelial-Mesenchymal Transition (EMT) Antibody Sampler Kit #9782 (all 1:1000 dilution) (CST, Boston, USA) were used for western blots. Besides, mouse anti-human primary antibody HIF-1α (Abcam, Cambridge, MA, USA), rabbit anti-human primary antibodies HIF-2α (Abcam, Cambridge, MA, USA), VEGFA (Abcam, Cambridge, MA, USA), EGFR (Abcam, Cambridge, MA, USA), c-Myc (CST, Boston, USA), Cyclin D1 (CST, Boston, USA) and MET (CST, Boston, USA) (all 1:1000 dilution) were also detected.

**Statistical analysis**

For the datasets from TCGA database, the software Perl, R (version 3.4.4), RStudio 1.2.1335-16 Windows 7+ (64-bit) and R packages were used for data integration, extraction, analysis and visualization. Briefly, the R package “edgeR” was utilized to screen differentially expressed genes (FDR < 0.05 and |log₂FC| > 2). The univariate cox regression and the Lasso regression were performed to identify key prognostic factors. The multivariate cox regression and K-M survival curve were performed to establish the risk score model and identify independent prognostic factors. ROC curve and C-index were performed to estimate the prognostic power of the risk score model. For the data about the function of LINC01234, SPSS 22.0 (IBM, USA) and GraphPad Prism 5.01 (GraphPad Software, USA) were used for statistical analyses. The data was expressed as mean ± SD from at least three independent experiments. Cell proliferation abilities...
of CCK-8 assay were compared with two-way ANOVA. Cell colony, migration and invasion levels, as well as qPCR data were compared using the Student’s t-test. A p < 0.05 was considered statistically significant.

**Results**

**Identification of differentially expressed lncRNAs and key prognostic lncRNAs in patients with ccRCC**

A total of 70 normal tissue samples and 541 cancer tissue samples from patients with ccRCC were collected. 11,368 lncRNAs were extracted from the transcriptome Profiling. Compared with the normal tissues, a total of 1541 lncRNAs were identified as differentially expressed lncRNAs in tumor tissues (FDR < 0.05 and |logFC| > 2), including 1075 upregulated (logFC > 2) and 466 downregulated (logFC < −2) lncRNAs (Figure 1A) (Supplementary Table S2).

Preliminary, a total of 323 statistically significant lncRNAs were considered to be related to the prognosis by the univariate cox regression (Supplementary Table S3). Next, through the LASSO regression, 13 lncRNAs were identified as key prognostic lncRNAs (Figure 1B, 1C), which were used for the further establishment of the risk score model by multivariate cox regression.

**Establishment and evaluation of the prognostic model in ccRCC**

The median cutoff point of the risk scores calculated by multivariate cox regression was 0.842. All patients were divided into the high-risk group and low-risk group. It was revealed that the patients in the high-risk group had a significantly worse overall survival rate than those in the low-risk group (p < 0.001) (Figure 2A). The AUC was 0.753 (3-year ROC curve) and 0.784 (5-year ROC curve) respectively, and the C-index was 0.753 (Figure 2B). In addition, it also presented the relationship between the survival time and the risk score for patients (the death and the alive) (Figure 2C). Moreover, a heatmap was plotted to illustrate the expression levels of the key prognostic lncRNAs in the high-risk group and low-risk group (Figure 2D).

**Identification of independent prognostic biomarkers**

The multivariate cox regression revealed HR and 95% CI for the 13 key prognostic lncRNAs with a forest plot (Figure 3). It indicated 6 statistically significant lncRNAs as the independent prognostic biomarkers, including lncRNAs AC009654.1, AC012615.3, AC092490.2, AL357507.1, LINC01234 and LINC01956. Moreover, K-M survival analysis was performed for the 6 lncRNAs. It revealed that all the 6 lncRNAs with high expression levels predicted a significantly worse overall survival rate than the low expressed one (Figure 4A-F). Therefore, they could serve as the adverse independent prognostic factors. Furthermore, we validated the expression levels and prognostic significance of the 6 lncRNAs in patients with ccRCC via GEPIA server. It suggested that AL357507.1, LINC01234, and LINC01956 were highly expressed at higher pathological stage of the disease, while LINC01234 exhibited the highest
significance in terms of expression at different pathological stage of the disease (Figure 5A-F).

Moreover, GEPIA server revealed the significance of LINC01234 in terms of survival time. The high expression level of LINC01234 predicted a significantly worse disease-free survival rate or overall survival rate than the low expressed one (Figure 5G, 5H). Unfortunately, GEPIA server could not provide the prognostic significance of the other 5 lncRNAs because the server showed the sample size was insufficient.

**LINC01234 knockdown suppressed the proliferation and clone formation of ccRCC cells**

Knockdown of LINC01234 was performed in Caki-2 and A498 cells by the lentivirus-mediated shRNA transfection. It suggested that the expression of LINC01234 was reduced in Caki-2 and A498 cells, which was validated by qPCR (Figure 6A). Next, the CCK-8 assay revealed the proliferations of Caki-2 and A498 cells were significantly suppressed (Figure 6B, 6C).

Moreover, cell colony formation assay was performed to analyze the role of LINC01234 in the colony formation of Caki-2 and A498 cells. As shown in Figure 6D-I, the clonogenic capacities of Caki-2 and A498 cells were dramatically inhibited. Obviously, it indicated that LINC01234 played an important role in the proliferation and colony formation of Caki-2 and A498 cells.

**LINC01234 depletion inhibited the migration and invasion of ccRCC cells**

The migration capabilities of Caki-2 and A498 cells were assessed by Transwell migration assay, while the invasion capabilities of these cells were assessed by Transwell Matrigel invasion assay. The results of the Transwell assay indicated that LINC01234 knockdown significantly inhibited the migration capabilities of Caki-2 and A498 cells (Figure 7A-F). Similarly, the invasion capabilities of Caki-2 and A498 cells were also suppressed following LINC01234 depletion (Figure 7G-L). These findings demonstrated that LINC01234 played an important role in the migration and invasion capacities of ccRCC cells.

**LINC01234 knockdown suppressed EMT process in ccRCC cells**

EMT process was closely related to the migration and invasion of cancer cells. Therefore, the mRNA levels of EMT-associated genes and the levels of EMT-associated proteins were detected by RT-PCR and western blots respectively. As shown in Figure 8A and 8B, we found that the mRNA level of epithelial marker E-cadherin was increased, while the mRNA level of mesenchymal marker N-cadherin was decreased in Caki-2 and A498 cells following LINC01234 knockdown. Similarly, as shown in Figure 8C, the protein expression levels of mesenchymal markers Vimentin and N-cadherin were significantly decreased in Caki-2 and A498 cells with LINC01234 knockdown, while the protein expression level of epithelial marker E-cadherin was upregulated. Moreover, the protein expression level of the transcription factor Snail was decreased in Caki-2 and A498 cells with LINC01234 knockdown. In addition, the protein expression level of β-catenin was also inhibited in Caki-2 and A498 cells following LINC01234 depletion.
LINC01234 suppression suppressed HIF-2α pathways in ccRCC cells

As shown in Figure 8A and 8B, we found that the mRNA levels of HIF-2α and vascular endothelial growth factor A (VEGFA) were decreased in Caki-2 and A498 cells following LINC01234 knockdown. Similarly, as shown in Figure 8D, we found that the protein expression levels of HIF-1α and HIF-2α were significantly decreased in Caki-2 and A498 cells with LINC01234 knockdown. Additionally, we found the protein expression levels of several target genes of HIF-2α, including VEGFA, epidermal growth factor receptor (EGFR), c-myc, Cyclin D1 and MET, were also inhibited in Caki-2 and A498 cells following LINC01234 depletion.

Discussion

LncRNA was a kind of long RNA transcripts (> 200 nucleotides) and it had no apparent protein-coding potentials (Quinn & Chang 2016). Even so, lncRNA possessed a wide range of biological functions involved in multiple vital cellular activities (Shen et al. 2015). Generally, lncRNA achieved its function by regulating gene expression in the levels of epigenetics, transcription and post-transcription (Lee 2012; Wang & Chang 2011). It could serve as a molecular signal, a molecular decoy, a molecular guide, or a molecular scaffold to achieve its functions (Wang & Chang 2011). The function of lncRNA was associated with its subcellular localization (Wang & Chang 2011). More specifically, lncRNA might be involved in chromatin regulation, gene transcription and alternative splicing of transcripts when it was in nucleus, while if it was in cytoplasm, it might serve as a competing endogenous RNA (ceRNA), and regulated the stability or translation of mRNA (Yang et al. 2019).

Recently, more and more evidences indicated that aberrations of lncRNA, such as overexpression, deficiency or mutation, played an important role in malignant phenotypes of cancers (Schmitt & Chang 2016), including tumor formation, progression, metastasis and poor prognosis (Esteller 2011; Gupta et al. 2010; Martens-Uzunova et al. 2014; Yu et al. 2017; Yue et al. 2016). Some aberrant lncRNAs were also associated with lots of malignant biological behaviors of cancer cells, such as proliferation, apoptosis, migration and invasion (Ellinger et al. 2016; Huang et al. 2017; Yue et al. 2016). It was also reported that some aberrant lncRNAs could serve as prognostic indicators in ccRCC, such as lncRNA Fer1L4 (Cox et al. 2020). With the development of molecular biological techniques and bioinformatics, more and more lncRNAs were marked as novel biomarkers and prognostic signatures for ccRCC utilizing TCGA database. For example, lncRNA Fer1L4 was overexpressed in ccRCC tissues, and its high expression levels were found in higher grade, higher stage, and metastatic tumors (Cox et al. 2020). LncRNA Fer1L4 overexpression was also an independent prognostic factor for patients with ccRCC (Cox et al. 2020). It was also reported an 11-lncRNA signature (AC245100.1, AP002761.1, LINC00488, AC017033.1, LINC-PINT, COL5A1-AS1, AC026471.4, ...
AL009181.1, LINC00524, HOTTIP, AL078590.3) and a 6-lncRNA signature (CTA-384D8.35, CTD-2263F21.1, LINC01510, RP11-352G9.1, RP11-395B7.2, RP11-426C22.4) were clearly linked to the overall survival (OS) rate of ccRCC patients based on TCGA database (Zeng et al. 2019; Zhang et al. 2019).

In the present study, utilizing the TCGA database, we identified 1541 differentially expressed lncRNAs. More importantly, we not only constructed a 13-lncRNA-based risk score model with moderate accuracy, but also identified 6 independent adverse prognostic lncRNAs for patients with ccRCC, including lncRNA AC009654.1, AC012615.3, AC092490.2, AL357507.1, LINC01234 and LINC01956. It was similar to a recent study which suggested that lncRNA AC009654.1, AC092490.2, LINC00524, LINC01234 and LINC01885 were significantly associated with ccRCC prognosis (Zhang et al. 2020). The expression levels of the 6 lncRNAs above were upregulated in ccRCC tissues and the high expression levels of them predicted a worse overall survival in ccRCC patients. Furtherly, we investigated their expression levels at different pathological stages and validated their prognostic significance in ccRCC patients via GEPIA server. It revealed AL357507.1, LINC01234, and LINC01956 were highly expressed at higher pathological stages of the disease, while LINC01234 exhibited the highest significance in terms of expression at different pathological stages of the disease. It was a very interesting finding, because the pathological stage was closely associated with the prognosis of ccRCC patients. Moreover, GEPIA server revealed the significance of LINC01234 in terms of survival time. Unfortunately, GEPIA server could not provide the prognostic significance of the other 5 lncRNAs because the server showed the sample size was insufficient. Besides, I also referred to the recent studies and references about these six lncRNAs. Nevertheless, except limited researches for LINC01234, there are no investigations for them currently and it deserves to further researches. Therefore, we mainly focused on lncRNA LINC01234 for the subsequent experiments.

Recently, partial functions and mechanisms of LINC01234 (also known as LCAL84) were reported in cancers, such as gastric cancer (Chen et al. 2018), esophageal cancer (Ghaffar et al. 2018), and colorectal adenocarcinoma (He et al. 2018). LINC01234 was upregulated and had oncogenic potentials in esophageal carcinoma cells in vitro (Ghaffar et al. 2018; He et al. 2018). LINC01234 was significantly associated with the prognosis of colorectal adenocarcinoma and the malignant biological behaviors of esophageal carcinoma cells including proliferation, migration, invasion and apoptosis (Ghaffar et al. 2018; He et al. 2018). Besides, LINC01234 expression was significantly upregulated in gastric cancer tissues and was associated with larger tumor size, advanced TNM stage, lymph node metastasis, and shorter survival time (Chen et al. 2018). Moreover, LINC01234 could serve as ceRNA to regulate core-binding factor β (CBFB) expression by sponging miR-204-5p to regulate the apoptosis, growth arrest and tumorigenesis in
gastric cancer (Chen et al. 2018). In our study, we also explored the role of LINC01234 in ccRCC. It indicated that LINC01234 expression was upregulated in ccRCC tissues. LINC01234 was expressed increasingly as the stage increased. The high expression level of LINC01234 predicted a significantly worse disease-free survival rate or overall survival rate than the low expressed one for the patients with ccRCC. Besides, LINC01234 knockdown inhibited proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) process of ccRCC cells. More importantly, LINC01234 knockdown impaired the expression of HIF-1a, HIF-2a, VEGFA, EGFR, c-Myc, Cyclin D1 and MET in Caki-2 and A498 cells following LINC01234 depletion.

EMT was considered as an essential process during development whereby epithelial cells acquired mesenchymal, fibroblast-like characteristics and displayed reduced intracellular adhesion and increased motility (Aigner et al. 2007; Moreno-Bueno et al. 2008). EMT played a critical role in the progression of primary tumors towards spread and metastasis, as well as the migration and invasion of malignant tumor cells (Gloushankova et al. 2018; Peinado et al. 2007; Yang et al. 2018). Recently, an increasing number of studies supported the role of lncRNAs in the regulation of tumor progression and metastasis through the regulation of EMT (Gugnoni & Ciarrocchi 2019). In the carcinogenic progression, downregulation of cell-adhesion molecules like epithelial cadherins, occludins, claudins, certain cytokeratins, and ZO-1 together with the coordinated upregulation of mesenchymal cadherins, vimentin, fibronectin and β1 and β3 integrins, promoted loss of cell-cell adhesion and apico-basal polarity and acquisition of invasive and migratory capacity (Gugnoni & Ciarrocchi 2019; Lu & Kang 2019). A group of transcription factors including Snail, Slug, Twist, zinc finger E-box-binding homeobox 1 and 2 (ZEB1, ZEB2) were well known to regulated EMT process partially or completely (Gugnoni & Ciarrocchi 2019; Yang et al. 2018). Therefore, we detected the mRNA levels of EMT-associated genes and the expression levels of EMT-associated proteins in ccRCC cells by qPCR and western blots respectively following LINC01234 knockdown. It revealed that the mRNA level of epithelial marker E-cadherin was increased, while the mRNA level of mesenchymal marker N-cadherin was decreased in Caki-2 and A498 cells following LINC01234 knockdown. The protein expression levels of the transcription factor Snail and the epithelial markers N-cadherin and Vimentin were reduced, while the protein expression level of the mesenchymal marker E-cadherin was up-regulated in A498 and Caki-2 cells with LINC01234 knockdown. These findings indicated that the function of LINC01234 was associated with EMT process. EMT was impaired after LINC01234 knockdown. In addition, we also found that inhibition of the β-catenin pathway contributed to the EMT impairment after LINC01234 depletion. All these evidences suggested that LINC01234 knockdown could inhibit the cell proliferation, migration and invasion, as well as EMT process in ccRCC. During EMT process, LINC01234 knockdown
might suppress the expression of transcription factor Snail, and further stimulate the expression
of E-cadherin, and inhibit the expressions of Vimentin and N-cadherin, which might result in a
inhibition of malignant biological behaviors of ccRCC cells, such as cell proliferation, migration
and invasion.

Hypoxia could induce ccRCC cells to undergo EMT, angiogenesis and metastasis (Meléndez-
Rodríguez et al. 2018; Zhang et al. 2017). Adaptation to a hypoxic environment played an
important role in the progression of ccRCC (Garje et al. 2018). Hypoxia was mediated via
hypoxia-inducible factors (Semenza 2012). Previously, HIF-1α was supposed to be a key
oncogenic factor, but recent evidence showed HIF-2α was a predominant driver in renal cancer
progression (Keith et al. 2011). Currently, HIF-1α is supposed to be a ccRCC tumor suppressor,
but the activity of HIF-1α is commonly diminished by chromosomal deletion in ccRCC (Schödel
et al. 2016). Conversely, HIF-2α has emerged as an oncogene that is essential for ccRCC tumor
progression (Meléndez-Rodríguez et al. 2018; Schödel et al. 2016). The polymorphisms at the
HIF-2α gene locus predispose to the development of ccRCC, and HIF-2α can promote tumor
growth (Schödel et al. 2016). Indeed, preclinical and clinical data have shown that
pharmacological inhibitors of HIF-2α can efficiently inhibit ccRCC growth (Meléndez-
Rodríguez et al. 2018). HIF-2α was found to be more sensitive to moderate hypoxia and showed
more enduring expression in hypoxic conditions (Zhang et al. 2017). HIF-2α could translocate to
the nucleus and bind to the hypoxia response elements (Garje et al. 2018). This binding resulted
in the expression of several target genes involved in angiogenesis, proliferation, migration and
invasion of cancer cells, such as VEGFA, EGFR, c-Myc, Cyclin D1 and MET (Garje et al.
2018). VEGFA played an important role in the formation of blood vessels, which was closely
associated with carcinogenesis (Shi et al. 2019). In ccRCC, as a well-known target of HIF-2α,
VEGFA also played a vital role in angiogenesis and was a key target of anti-cancer therapeutic
agents (Garje et al. 2018; Meléndez-Rodríguez et al. 2018). Besides, EGFR, c-Myc and Cyclin
D1 were associated with ccRCC cell cycle and proliferation (Meléndez-Rodríguez et al. 2018).
EGFR signaling could also promote ccRCC survival (Meléndez-Rodríguez et al. 2018).
Moreover, MET was related to ccRCC metastasis (Meléndez-Rodríguez et al. 2018). Based on
this above, we detected HIF-2α pathways after LINC01234 depletion. It revealed that the mRNA
levels of HIF-2α and VEGFA were decreased in A498 and Caki-2 cells with LINC01234
knockdown. Similarly, the expression levels of proteins HIF-2α, VEGFA, EGFR, c-Myc, Cyclin
D1 and MET were reduced in A498 and Caki-2 cells with LINC01234 knockdown. In our study,
LINC01234 was expressed increasingly as the stage increased and its high expression level
predicted a significantly worse disease-free survival rate or overall survival rate for the patients
with ccRCC. LINC01234 knockdown suppressed cell proliferation, migration and invasion of
ccRCC cells. Combined with all these findings above, it suggested that LINC01234 knockdown
might suppress the expression of HIF-2α, and then inhibit the expression of VEGFA, EGFR, c-Myc, Cyclin D1 and MET, which might further inhibit the proliferation, metastasis and survival of ccRCC.

Unfortunately, there was several limitations in our study. Firstly, the function of IncRNA was associated with its subcellular localization, but we did not identify the subcellular localization of LINC01234 in ccRCC cell lines. Secondly, although LINC01234 functioned as ceRNA to regulate CBFB expression by sponging miR-204-5p in gastric cancer, we did not identify any miRNAs as direct targets of LINC01234 to investigate whether LINC01234 was a ceRNA for miRNAs in ccRCC. It deserves to more investigations.

Conclusions

In summary, we constructed a IncRNA-based prognostic model with moderate accuracy and identified LINC01234 as an independent prognostic biomarker in ccRCC. Moreover, LINC01234 knockdown might inhibit the proliferation and metastasis of ccRCC cells by suppressing HIF-2α pathways. Therefore, LINC01234 might serve as a promising prognostic biomarker and a potential therapeutic target for patients with ccRCC.

Acknowledgements

We specially gratitude to The Cancer Genome Atlas (TCGA) project (https://portal.gdc.cancer.gov/) for its valuable public data set.

References

Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, and Eger A. 2007. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26:6979-6988. 10.1038/sj.onc.1210508

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, and Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424. 10.3322/caac.21492

Chen X, Chen Z, Yu S, Nie F, Yan S, Ma P, Chen Q, Wei C, Fu H, Xu T, Ren S, Sun M, and Wang Z. 2018. Long Noncoding RNA LINC01234 Functions as a Competing Endogenous RNA to Regulate CBFB Expression by Sponging miR-204-5p in Gastric Cancer. Clin Cancer Res 24:2002-2014. 10.1158/1078-0432.ccr-17-2376

Cheng P. 2018. A prognostic 3-long noncoding RNA signature for patients with gastric cancer. J Cell Biochem 119:9261-9269. 10.1002/jcb.27195
Cox A, Tolkach Y, Kristiansen G, Ritter M, and Ellinger J. 2020. The lncRNA Fer1L4 is an adverse prognostic parameter in clear-cell renal-cell carcinoma. *Clin Transl Oncol.* 10.1007/s12094-020-02291-0

Deng M, Bragelmann J, Schultz JL, and Perner S. 2016. Web-TCGA: an online platform for integrated analysis of molecular cancer data sets. *BMC Bioinformatics* 17:72. 10.1186/s12859-016-0917-9

Ellinger J, Gevensleben H, Muller SC, and Dietrich D. 2016. The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma. *Expert Rev Mol Diagn* 16:1059-1065. 10.1080/14737159.2016.1239531

Esteller M. 2011. Non-coding RNAs in human disease. *Nat Rev Genet* 12:861-874. 10.1038/nrg3074

Garje R, An JJ, Sanchez K, Greco A, Stolwijk J, Devor E, Rustum Y, and Zakharia Y. 2018. Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment. *Int J Mol Sci* 19. 10.3390/ijms19123834

Ghaffar M, Khodahemmati S, Li J, Shahzad M, Wang M, Wang Y, Li C, Chen S, and Zeng Y. 2018. Long Non-coding RNA LINC01234 Regulates Proliferation, Invasion and Apoptosis in Esophageal Cancer Cells. *J Cancer* 9:4242-4249. 10.7150/jca.26095

Gloushankova NA, Zhitnyak IY, and Rubtsova SN. 2018. Role of Epithelial-Mesenchymal Transition in Tumor Progression. *Biochemistry (Mosc)* 83:1469-1476. 10.1134/s0006297918120052

Gugnoni M, and Ciarrocchi A. 2019. Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer. *Int J Mol Sci* 20. 10.3390/ijms20081924

Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumaran S, and Chang HY. 2010. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature* 464:1071-1076. 10.1038/nature08975

He Z, Dang J, Song A, Cui X, Ma Z, and Zhang Z. 2018. Identification of LINC01234 and MIR210HG as novel prognostic signature for colorectal adenocarcinoma. *J Cell Physiol.* 10.1002/jcp.27424

Huang HW, Xie H, Ma X, Zhao F, and Gao Y. 2017. Upregulation of LncRNA PANDAR predicts poor prognosis and promotes cell proliferation in cervical cancer. *Eur Rev Med Pharmacol Sci* 21:4529-4535.

Jin Y, Feng SJ, Qiu S, Shao N, and Zheng JH. 2017. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway. *Eur Rev Med Pharmacol Sci* 21:3176-3184.
Keith B, Johnson RS, and Simon MC. 2011. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic
tumour growth and progression. *Nat Rev Cancer* 12:9-22. 10.1038/nrc3183

Lee JT. 2012. Epigenetic regulation by long noncoding RNAs. *Science* 338:1435-1439.
10.1126/science.1231776

Liu C, Wang C, Wang K, Liu L, Shen Q, Yan K, Sun X, Chen J, Liu J, Ren H, Liu H, Xu Z, Hu S,
Xu D, and Fan Y. 2013. SMYD3 as an oncogenic driver in prostate cancer by stimulation
of androgen receptor transcription. *J Natl Cancer Inst* 105:1719-1728.
10.1093/jnci/djt304

Lu W, and Kang Y. 2019. Epithelial-Mesenchymal Plasticity in Cancer Progression and
Metastasis. *Dev Cell* 49:361-374. 10.1016/j.devcel.2019.04.010

Martens-Uzunova ES, Bottcher R, Croce CM, Jenster G, Visakorpi T, and Calin GA. 2014. Long
noncoding RNA in prostate, bladder, and kidney cancer. *Eur Urol* 65:1140-1151.
10.1016/j.eururo.2013.12.003

Meléndez-Rodríguez F, Roche O, Sanchez-Prieto R, and Aragones J. 2018. Hypoxia-Inducible
Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer. *Front
Oncol* 8:214. 10.3389/fonc.2018.00214

Moreno-Bueno G, Portillo F, and Cano A. 2008. Transcriptional regulation of cell polarity in EMT
and cancer. *Oncogene* 27:6958-6969. 10.1038/onc.2008.346

Peinado H, Olmeda D, and Cano A. 2007. Snail, Zeb and bHLH factors in tumour progression:
an alliance against the epithelial phenotype? *Nat Rev Cancer* 7:415-428.
10.1038/nrc2131

Ponting CP, Oliver PL, and Reik W. 2009. Evolution and functions of long noncoding RNAs. *Cell
136:629-641. 10.1016/j.cell.2009.02.006

Quinn JJ, and Chang HY. 2016. Unique features of long non-coding RNA biogenesis and
function. *Nat Rev Genet* 17:47-62. 10.1038/nrg.2015.10

Rinn JL, and Chang HY. 2012. Genome regulation by long noncoding RNAs. *Annu Rev
Biochem* 81:145-166. 10.1146/annurev-biochem-051410-092902

Schmitt AM, and Chang HY. 2016. Long Noncoding RNAs in Cancer Pathways. *Cancer Cell
29:452-463. 10.1016/j.ccell.2016.03.010

Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, and Mole DR. 2016. Hypoxia,
Hypoxia-inducible Transcription Factors, and Renal Cancer. *Eur Urol* 69:646-657.
10.1016/j.eururo.2015.08.007

Semenza GL. 2012. Hypoxia-inducible factors: mediators of cancer progression and targets for
cancer therapy. *Trends Pharmacol Sci* 33:207-214. 10.1016/j.tips.2012.01.005

Shen Y, Wang Z, Loo LW, Ni Y, Jia W, Fei P, Risch HA, Katsaros D, and Yu H. 2015.
LINC00472 expression is regulated by promoter methylation and associated with
493 disease-free survival in patients with grade 2 breast cancer. *Breast Cancer Res Treat*
494 154:473-482. 10.1007/s10549-015-3632-8
495 Shi J, Zhang D, Zhong Z, and Zhang W. 2019. IncRNA ROR promotes the progression of renal
496 cell carcinoma through the miR-206/VEGF axis. *Mol Med Rep* 20:3782-3792.
497 10.3892/mmr.2019.10636
498 Song E, Song W, Ren M, Xing L, Ni W, Li Y, Gong M, Zhao M, Ma X, Zhang X, and An R. 2018.
499 Identification of potential crucial genes associated with carcinogenesis of clear cell renal
500 cell carcinoma. *J Cell Biochem* 119:5163-5174. 10.1002/jcb.26543
501 Tang Z, Li C, Kang B, Gao G, Li C, and Zhang Z. 2017. GEPIA: a web server for cancer and
502 normal gene expression profiling and interactive analyses. *Nucleic Acids Res* 45:W98-
503 w102. 10.1093/nar/gkx247
504 Wang G, Huang Y, Yang F, Tian X, Wang K, Liu L, Fan Y, Li X, Li L, Shi B, Hao Y, Xia C, Nie Q,
505 Xin Y, Shi Z, Ma L, Xu D, and Liu C. 2020. High expression of SMYD3 indicates poor
506 survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1
507 positive feedback loop in bladder cancer. *Aging (Albany NY)* 12:2030-2048.
508 10.18632/aging.102718
509 Wang KC, and Chang HY. 2011. Molecular mechanisms of long noncoding RNAs. *Mol Cell
510* 43:904-914. 10.1016/j.molcel.2011.08.018
511 Yang F, Song Y, Ge L, Zhao G, Liu C, and Ma L. 2019. Long non-coding RNAs as prognostic
512 biomarkers in papillary renal cell carcinoma. *Oncol Lett* 18:3691-3697.
513 10.3892/ol.2019.10684
514 Yang F, Yu N, Wang H, Zhang C, Zhang Z, Li Y, Li D, Yan L, Liu H, and Xu Z. 2018.
515 Downregulated expression of hepatoma-derived growth factor inhibits migration and
516 invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and
517 MMP2, MMP9. *PLoS One* 13:e0190725. 10.1371/journal.pone.0190725
518 Yu Y, Yang J, Li Q, Xu B, Lian Y, and Yao L. 2017. LINC00152: A pivotal oncogenic long non-
519 coding RNA in human cancers. *Cell Prolif* 50. 10.1111/cpr.12349
520 Yue B, Qiu S, Zhao S, Liu C, Zhang D, Yu F, Peng Z, and Yan D. 2016. LncRNA-ATB mediated
521 E-cadherin repression promotes the progression of colon cancer and predicts poor
522 prognosis. *J Gastroenterol Hepatol* 31:595-603. 10.1111/jgh.13206
523 Zeng JH, Lu W, Liang L, Chen G, Lan HH, Liang XY, and Zhu X. 2019. Prognosis of clear cell
524 renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation
525 based on RNA-sequencing data. *J Transl Med* 17:281. 10.1186/s12967-019-2032-y
526 Zhang C, Huang D, Liu A, Xu Y, Na R, and Xu D. 2020. Genome-wide screening and cohorts
527 validation identifying novel lncRNAs as prognostic biomarkers for clear cell renal cell
528 carcinoma. *J Cell Biochem* 121:2559-2570. 10.1002/jcb.29478
Zhang J, Zhang X, Piao C, Bi J, Zhang Z, Li Z, and Kong C. 2019. A long non-coding RNA signature to improve prognostic prediction in clear cell renal cell carcinoma. *Biomed Pharmacother* 118:109079. 10.1016/j.biopha.2019.109079

Zhang Q, Lou Y, Zhang J, Fu Q, Wei T, Sun X, Chen Q, Yang J, Bai X, and Liang T. 2017. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. *Mol Cancer* 16:119. 10.1186/s12943-017-0689-5
Figure 1

*Identification of differentially expressed IncRNAs and key prognostic IncRNAs in patients with ccRCC.*

(A) Identification of differentially expressed IncRNAs. A total of 11,368 IncRNAs were extracted from the transcriptome profiling and 1541 IncRNAs were identified as differentially expressed IncRNAs in tumor tissues, including 1075 upregulated (logFC > 2) and 466 downregulated (logFC < −2) IncRNAs. (B, C) Tuning parameter and variable selection by LASSO regression to identify key prognostic IncRNAs. A total of 323 significant IncRNAs were preliminarily associated with prognosis by the univariate cox regression, and finally 13 key prognostic IncRNAs were identified by LASSO regression. The numbers on the top of the figures indicated the number of the candidate IncRNAs for the corresponding lambda (λ) value in LASSO regression. IncRNA, long non-coding RNA; FC, fold change; LASSO, least absolute shrinkage and selection operator.
Figure 2

Establishment and evaluation of the prognostic model.

(A) K-M survival curve of the risk level. By multivariate cox regression based on the 13 key prognostic IncRNAs, the prognostic model was established and the patients were divided into high-risk and low-risk group. It revealed that the patients in the high-risk group had significantly worse OS rate than that of the low-risk group (p < 0.05). (B) 3-year and 5-year ROC curves and C-index of the 13 key prognostic IncRNAs. AUC=0.753 (3-year ROC) and AUC=0.784 (5-year ROC), C-index=0.753. (C) The distribution landscape of the alive and the dead of ccRCC cases in the coordinate system of risk score and survival time. (D) Heatmap of the expression levels of the 13 key prognostic IncRNAs in the high-risk group and low-risk group. The red and blue represent increased and decreased normalized expression value of the IncRNAs in all patients, respectively. K-M, Kaplan-Meier; ROC, receiver operating characteristic; AUC, area under curve; IncRNAs, long non-coding RNAs; OS, overall survival; ccRCC, clear cell renal cell carcinoma.
A

![Graph A](image)

B

![Graph B](image)

C

![Graph C](image)

D

![Graph D](image)
Figure 3

HR and 95% CI of the 13 key prognostic IncRNAs by multivariate cox regression.

A total of 528 patients were included in the analysis. Of the 13 key prognostic IncRNAs, six had a significant influence on the OS rate of ccRCC patients, including AC009654.1, AC012615.3, AC092490.2, AL357507.1, LINC01234 and LINC01956 (all $p < 0.05$). HR, hazard ratio; CI, confidence interval; IncRNA, long non-coding RNA; ccRCC, clear cell renal cell carcinoma; OS, overall survival.
| Manuscript ID    | Hazard Ratio | Hazard Ratio (95% CI) | p-value |
|------------------|--------------|-----------------------|---------|
| AC009654.1       | 1.15         | (1.02 – 1.3)          | 0.024 * |
| AC012615.3       | 1.26         | (1.01 – 1.6)          | 0.038 * |
| AC018695.6       | 1.06         | (0.96 – 1.2)          | 0.27    |
| AC092490.2       | 1.12         | (1.01 – 1.2)          | 0.027 * |
| AC138305.2       | 1.07         | (0.95 – 1.2)          | 0.263   |
| AC245041.2       | 0.98         | (0.90 – 1.1)          | 0.692   |
| AL357507.1       | 1.13         | (1.04 – 1.2)          | 0.005 **|
| AL358876.2       | 1.13         | (1.00 – 1.3)          | 0.055   |
| LINC00524        | 1.06         | (0.97 – 1.2)          | 0.175   |
| LINC00845        | 0.89         | (0.78 – 1.0)          | 0.076   |
| LINC01234        | 1.07         | (1.00 – 1.1)          | 0.045 * |
| LINC01885        | 0.93         | (0.85 – 1.0)          | 0.147   |
| LINC01956        | 1.11         | (1.01 – 1.2)          | 0.029 * |
Figure 4

*K-M survival curves of the six independent prognostic lncRNAs identified by multivariate cox regression.*

It showed that the high expression levels of the lncRNAs, including AC009654.1 (A), AC012615.3 (B), AC092490.2 (C), AL357507.1 (D), LINC01234 (E) and LINC01956 (F), were correlated with the worse OS rate of patients with ccRCC (all p < 0.05). K-M, Kaplan-Meier; OS, overall survival; ccRCC, clear cell renal cell carcinoma; lncRNA, long non-coding RNA.
Figure 5

Validation of the expression and prognostic significance of the six independent prognostic IncRNAs by GEPIA server.

(A-F) Expression levels of the 6 independent prognostic IncRNAs in different stages of patients with ccRCC. It suggested that AL357507.1, LINC01234, and LINC01956 were highly expressed at higher pathological stage of the disease, while LINC01234 exhibited the highest significance in terms of expression levels at different pathological stage of the disease. (G, H) Prognostic significance of LINC01234 in patients with ccRCC. It showed the high expression level of LINC01234 predicted a significantly worse disease-free survival rate or overall survival rate than that of the low expressed (all p < 0.05). ccRCC, clear cell renal cell carcinoma; GEPIA, Gene Expression Profiling Interactive Analysis.
Figure 6

LINC01234 knockdown suppressed the proliferation and colony formation of ccRCC cells.

(A) QPCR analysis verified that LINC01234 was down-regulated in Caki-2 and A498 cells (all $p < 0.05$). (B, C) CCK-8 assays showed that LINC01234 knockdown reduced the proliferation of Caki-2 and A498 cells respectively (all $p < 0.05$). (D-I) Colony formation assays showed that LINC01234 knockdown reduced the colony formation capabilities of Caki-2 and A498 cells respectively (all $p < 0.05$). *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$; ccRCC, clear cell renal cell carcinoma.
Figure 7

LINC01234 knockdown inhibited the migration and invasion of ccRCC cells.

Cell migration and invasion capacities were measured by Transwell assay. Representative images (magnification, × 100) were presented. It indicated that the migration abilities of Caki-2 (A-C) and A498 (D-F) cells were reduced following LINC01234 knockdown (all \( p < 0.05 \)). The invasion abilities of Caki-2 (G-I) and A498 (J-L) cells were also inhibited following LINC01234 knockdown (all \( p < 0.05 \)). ****, \( p < 0.0001 \); ccRCC, clear cell renal cell carcinoma.
Manuscript to be reviewed

Caki-2

control | shRNA

A

B

C

Cell migration number/field

control | shRNA

****

A498

control | shRNA

D

E

F

Cell migration number/field

control | shRNA

****

Caki-2

control | shRNA

G

H

I

Cell invasion number/field

control | shRNA

****

A498

control | shRNA

J

K

L

Cell invasion number/field

control | shRNA

****
Figure 8

EMT process and HIF-2α pathways were inhibited in ccRCC cells following LINC01234 knockdown.

(A, B) The mRNA levels of N-cadherin, HIF-2α and VEGFA were reduced, while that of E-cadherin was upregulated in ccRCC cells with LINC01234 knockdown. (C) EMT process was inhibited in ccRCC cells with LINC01234 knockdown. The protein expression levels of β-catenin, Snail, N-cadherin and Vimentin were reduced, while that of E-cadherin was increased in Caki-2 and A498 cells with LINC01234 knockdown. (D) HIF-2α pathway was inhibited in ccRCC cells with LINC01234 knockdown. The protein expression levels of HIF-1α, HIF-2α, VEGFA, EGFR, c-Myc, Cyclin D1 and MET were reduced in A498 and Caki-2 cells with LINC01234 knockdown. EMT, epithelial-mesenchymal transition; ccRCC, clear cell renal cell carcinoma.
